ARTENIMOL
Trials 61 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07007078 | Jun 2025 → May 2026 overdue | acne | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT02568098 | Oct 2015 → Dec 2016 | — | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02184637 | Jul 2014 → Apr 2015 | Plasmodium vivax malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01222962 | Mar → May 2010 | Plasmodium falciparum malaria | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07679542 | Mar → Jun 2026 overdue | metabolic dysfunction-associated steatotic liver disease | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07557927 | Apr 2026 → Sep 2028 expected | discoid lupus erythematosus | Kunming Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06417099 | May 2024 → Mar 2025 | polycystic ovary syndrome | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05252845 | Jan → Jun 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT05829187 | Nov → Dec 2022 | Plasmodium falciparum malaria | Syamsudin Abdillah,Ph.D, Pharm D | Completed | No outcome recorded |
| Phase 2 | NCT03396393 | Mar 2018 → Dec 2021 | systemic lupus erythematosus | Kunming Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT02909712 | Sep 2016 → Jan 2020 | malaria, parasitemia, poisoning | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT04009343 | Jun 2019 → Aug 2020 overdue | Plasmodium falciparum malaria | Johns Hopkins Bloomberg School of Public Health | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02461186 | Jun 2015 → Jun 2017 | Plasmodium falciparum malaria | University of Oxford | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00941785 | Jul → Dec 2009 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT00561899 | Aug 2007 → Feb 2008 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT06962319 | Sep 2025 → Aug 2028 expected | malaria | Liverpool School of Tropical Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT05946642 | Jul 2023 → May 2024 | malaria | Malaria Consortium | Unknown | No outcome recorded |
| Phase 3 | NCT04844099 | Apr 2021 → Jun 2023 | malaria, sickle cell disease | Liverpool School of Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT04147546 | Aug 2020 → Aug 2021 | Plasmodium falciparum malaria | Institut de Recherche en Sciences de la Sante, Burkina Faso | Completed | No outcome recorded |
| Phase 3 | NCT04158713 | Nov 2019 → Apr 2022 | — | Liverpool School of Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03671109 | Sep 2019 → Jul 2022 | HIV infectious disease, malaria, pregnancy disorder | Barcelona Institute for Global Health | Completed | No outcome recorded |
| Phase 3 | NCT03576313 | Aug 2018 → Dec 2019 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT03208907 | Jul 2018 → Jul 2021 | Plasmodium vivax malaria | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Completed | No outcome recorded |
| Phase 3 | NCT01899820 | Apr 2013 → Jun 2014 | malaria | Sabah Ahmed Omar | Unknown | No outcome recorded |
| Phase 3 | NCT01640574 | Feb 2012 → Jul 2015 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT01231113 | Jul 2011 → Dec 2012 | Plasmodium falciparum malaria | Kwame Nkrumah University of Science and Technology | Completed | No outcome recorded |
| Phase 3 | NCT01231880 | Feb 2011 → Sep 2012 | malaria | Makerere University | Completed | No outcome recorded |
| Phase 3 | NCT01288820 | Jan 2011 → Apr 2012 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00948896 | Jun 2010 → Apr 2014 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT01082705 | Apr 2010 → Jun 2011 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT01845701 | Mar 2010 → Apr 2014 | malaria | University of Yaounde 1 | Completed | No outcome recorded |
| Phase 3 | NCT01054248 | Feb 2010 → Sep 2016 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00682578 | Jul 2007 → Feb 2010 | Plasmodium falciparum malaria, Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00393679 | Jul 2007 → Dec 2009 | malaria | Institute of Tropical Medicine, Belgium | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT07246525 | Aug 2026 → Aug 2029 expected | malaria | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06347471 | May 2024 → Nov 2025 | Plasmodium falciparum malaria | Infectious Diseases Research Collaboration, Uganda | Completed | No outcome recorded |
| Phase 4 | NCT06225297 | Jan → Dec 2024 | malaria | PATH | Suspended | No outcome recorded |
| Phase 4 | NCT05788094 | Jun 2023 → Feb 2026 overdue | Plasmodium vivax malaria | Shoklo Malaria Research Unit | Recruiting | No outcome recorded |
| Phase 4 | NCT05465135 | Jul 2022 → Mar 2023 | polycystic ovary syndrome | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05340153 | Apr → Dec 2022 | malaria | University of Yaounde 1 | Unknown | No outcome recorded |
| Phase 4 | NCT05294406 | Feb 2022 → Dec 2023 | malaria | Liverpool School of Tropical Medicine | Completed | No outcome recorded |
| Phase 4 | NCT04816461 | Jul 2021 → Jun 2023 | malaria | Institut de Recherche en Sciences de la Sante, Burkina Faso | Completed | No outcome recorded |
| Phase 4 | NCT02940756 | Mar 2017 → Jan 2018 | malaria | Ministry of Public Health, Democratic Republic of the Congo | Completed | No outcome recorded |
| Phase 4 | NCT02654912 | Feb 2016 → Jun 2020 | malaria | PATH | Completed | No outcome recorded |
| Phase 4 | NCT02324738 | Jan → May 2015 | — | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT02325180 | Jan → Jun 2015 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01669941 | Aug 2012 → Oct 2014 | malaria, pregnancy disorder | Kenya Medical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01651416 | Jul → Dec 2012 | anemia, malaria | Centre for Global Health Research, Ghana | Completed | No outcome recorded |
| Phase 4 | NCT01389557 | Feb → Nov 2011 | malaria | Indonesia University | Completed | No outcome recorded |
| Phase 4 | NCT00902811 | Dec 2008 → Oct 2009 | Plasmodium falciparum malaria | Medecins Sans Frontieres, Netherlands | Unknown | No outcome recorded |
| Phase 4 | NCT00845533 | Aug → Dec 2007 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT07281443 | Sep 2024 → Dec 2026 expected | Plasmodium falciparum malaria, parasitemia | Research Institute for Development | Active not recruiting | No outcome recorded |
| — | NCT04864444 | Jun 2021 → Dec 2022 | Plasmodium falciparum malaria | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT02329301 | Sep 2014 → Jun 2016 | Plasmodium falciparum malaria | PATH | Completed | No outcome recorded |
| — | NCT02001428 | Jul 2014 → Mar 2016 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Gadjah Mada University | Completed | No outcome recorded |
| — | NCT01640587 | Nov 2013 → Mar 2017 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| — | NCT01872702 | Apr 2013 → Jul 2017 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| — | NCT01624337 | May 2012 → Aug 2014 | malaria | Armed Forces Research Institute of Medical Sciences, Thailand | Terminated | No outcome recorded |
| — | NCT01326754 | Aug 2011 → Jun 2012 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| — | NCT00868465 | Apr 2009 → May 2010 | malaria | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00157833 | Jul 2004 → Aug 2005 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Menzies School of Health Research | Completed | No outcome recorded |
Also used as a comparator or background therapy in 42 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07012486 Comparator | Jun 2025 → May 2026 overdue | androgenetic alopecia | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02614404 Background | Nov 2015 → Dec 2016 | Plasmodium falciparum malaria | HuLow | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02802813 Comparator | Jun 2016 → Jun 2018 | Plasmodium vivax malaria | University of Oxford | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT06842524 Comparator | Apr 2025 → Sep 2026 expected | polycystic ovary syndrome | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04661579 Background | Nov 2020 → Jun 2022 | Plasmodium falciparum malaria | PATH | Completed | No outcome recorded |
| Phase 2 | NCT04609098 Background | Oct → Dec 2020 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT06036030 Comparator | Jan → Apr 2019 | Plasmodium falciparum malaria, Plasmodium vivax malaria | Syamsudin Abdillah,Ph.D, Pharm D | Completed | No outcome recorded |
| Phase 2 | NCT03697668 Comparator | Sep 2017 → Dec 2018 | Plasmodium falciparum malaria | Nurex S.r.l. | Unknown | No outcome recorded |
| Phase 2 | NCT02831023 Comparator | Jul 2016 → Jan 2017 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT01992900 Comparator | Nov 2013 → Jul 2015 | Plasmodium falciparum malaria | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01743820 Background | Sep 2013 → Dec 2014 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04049916 Comparator | Sep 2019 → Jan 2020 | Plasmodium falciparum malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT02654730 Comparator | Dec 2015 → Sep 2016 | malaria | London School of Hygiene and Tropical Medicine | Terminated | No outcome recorded |
| Phase 2/3 | NCT02453308 Comparator | Aug 2015 → Mar 2018 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT07082205 Comparator | May 2025 → Sep 2026 expected | anemia, malaria | Liverpool School of Tropical Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT06516042 Comparator | Aug 2024 → Jan 2025 overdue | Plasmodium falciparum malaria | PATH | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04978272 Comparator | Feb 2022 → May 2027 expected | malaria | Grant Dorsey, M.D, Ph.D. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04660110 Comparator | Jan → Jun 2021 | malaria | Makerere University | Unknown | No outcome recorded |
| Phase 3 | NCT04189744 Comparator | Dec 2019 → Oct 2022 | Trichomonas vaginitis urogenital infection, bacterial vaginosis, malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT04149106 Comparator | Jul 2019 → Dec 2022 | Plasmodium falciparum malaria | University Clinical Research Center, Mali | Unknown | No outcome recorded |
| Phase 3 | NCT02793622 Comparator | Sep 2016 → Dec 2018 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT02671175 Comparator | May 2016 → Oct 2018 | anemia, malaria | Liverpool School of Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02282293 Comparator | Dec 2014 → May 2016 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT01838902 Background | Aug 2013 → Feb 2015 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02974348 Comparator | Jan → May 2013 | Plasmodium falciparum malaria | University of Bamenda | Completed | No outcome recorded |
| Phase 3 | NCT00852371 Comparator | Feb → Jun 2008 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00529620 Comparator | Sep → Dec 2007 | malaria | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT07403643 Background | Apr → Dec 2026 expected | malaria | Curtin University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06068530 Comparator | Feb 2025 → Feb 2028 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 4 | NCT05323721 Comparator | Jun → Nov 2022 | malaria | Malaria Consortium | Unknown | No outcome recorded |
| Phase 4 | NCT05343312 Comparator | Mar 2022 → Sep 2023 | Plasmodium falciparum malaria | Manhiça Health Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT04767191 Comparator | Mar 2021 → Dec 2022 | malaria | Jhpiego | Completed | No outcome recorded |
| Phase 4 | NCT03178643 Comparator | Jan 2018 → Dec 2020 | Plasmodium falciparum malaria | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT02604966 Comparator | Apr 2015 → Sep 2016 | Plasmodium falciparum malaria | National Institute of Malariology, Parasitology and Entomology, Vietnam | Unknown | No outcome recorded |
| Phase 4 | NCT02434952 Background | Oct 2014 → Jul 2016 | G6PD deficiency, Plasmodium falciparum malaria | Malaria Consortium | Completed | No outcome recorded |
| Phase 4 | NCT02118090 Comparator | May → Dec 2014 | Plasmodium vivax malaria | Institut Pasteur, Cambodia | Completed | No outcome recorded |
| Phase 4 | NCT01930331 Comparator | Jan → Jul 2014 | Plasmodium falciparum malaria | Ifakara Health Institute | Completed | No outcome recorded |
| Phase 4 | NCT01887821 Comparator | Feb 2013 → Jun 2015 | Plasmodium vivax malaria | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 4 | NCT01704508 Comparator | Nov 2012 → Oct 2015 | Plasmodium falciparum malaria | Bandim Health Project | Completed | No outcome recorded |
| Phase 4 | NCT01392014 Comparator | Dec 2008 → Mar 2010 | Plasmodium falciparum malaria | Indonesia University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07533136 Comparator | May 2026 → Oct 2028 expected | Plasmodium vivax malaria | Walter Reed Army Institute of Research (WRAIR) | Not yet recruiting | No outcome recorded |
| — | NCT07389057 Comparator | Nov 2023 → Nov 2026 expected | Plasmodium falciparum malaria, parasitemia | Noguchi Memorial Institute for Medical Research | Recruiting | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 108 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARTENIMOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | .beta.-dihydroartemisinin | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | Alaxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | Artemether related compound a | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | Artenimol component of eurartesim dihydroartemisinin | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | Artenimolum | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | Cotecxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | Cotexin | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | DHA | “Our previous single-arm pilot trial showed that dihydroartemisinin (DHA) normalised menstrual cycles, ameliorated hyperandrogenaemia and reduced antral follicles in individuals...” PMID 42320967 ↗ Jun 202611“SP plus amodiaquine (AQ), SP plus piperaquine (PQ) or dihydroartemisinin (DHA) plus PQ at monthly intervals on three occasions during the peak malaria transmission season.” PMID 20574538 ↗ Jun 2010 “Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) will be administered on Day 1 and at 24 hours (Day 2) and 48 hours (Day 3) post first dose administration” NCT02184637 ↗ “including dihydroartemisinin (DHA)-piperaquine + mefloquine, is a potential treatment option for multidrug-resistant Plasmodium falciparum malaria” PMID 31182525 ↗ Jul 2019 “Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.” NCT01222962 ↗ “DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.” NCT00393679 ↗ “Eurartesim is a fixed-dose combination product composed of dihydroartemisinin (DHA) and piperaquine phosphate (PQP).” NCT01992900 ↗ “one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP).” NCT02118090 ↗ “dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults.” NCT07012486 ↗ “dihydroartemisin (DHA) or sulfadoxine-pyrimethamine (SP)” PMID 19784374 ↗ Sep 2009 “Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)” NCT00682578 ↗ “DHA (dihydroartemisinin) Arm” NCT07007078 ↗ |
| Known as | Di-hydroqinghaosu | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | dihydroartemisinin | “At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women...” NCT01669941 ↗100“Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a...” NCT06068530 ↗ “Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day...” NCT05252845 ↗ “Our aim was to compare the safety and efficacy of dihydroartemisinin-piperaquine with that of artemether-lumefantrine in patients with uncomplicated malaria caused by...” PMID 17336652 ↗ Mar 2007 “Sixty patients received either dihydroartemisinin/piperaquine (4 mg/kg/day, 3 days; n = 33) or artesunate monotherapy (4 mg/kg/day, 3 days; n = 27) followed by...” PMID 32437557 ↗ Aug 2020 “Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana” NCT07389057 ↗ “The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).” NCT02654912 ↗ “Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects” NCT02568098 ↗ “40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups.” NCT00902811 ↗ “Administration of imatinib (400 mg/day) plus dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients.” NCT02614404 ↗ “Three monthly cycles of targeted chemoprevention with dihydroartemisinin-piperaquine (DHA-PQ) for all daara residents, regardless of resident age” NCT06225297 ↗ “Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.” NCT01222962 ↗ “Eurartesim is a fixed-dose combination product composed of dihydroartemisinin (DHA) and piperaquine phosphate (PQP).” NCT01992900 ↗ “Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days” NCT00561899 ↗ “Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia” NCT02329301 ↗ “one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP).” NCT02118090 ↗ “dihydroartemisinin-piperaquine (DHAP) alone or combined with single dose of primaquine (PQ)” PMID 27825738 ↗ Oct 2016 “dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days” NCT00941785 ↗ “dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults.” NCT07012486 ↗ “a 3-day course of dihydroartemisinin with piperaquine-phosphate” PMID 29522113 ↗ Aug 2018 “half tablet (40mg dihydroartemisinin e 320 mg piperaquine)” NCT05343312 ↗ “Dihydroartemisinin/Piperaquine (DHA-PQP or Eurartesim®)” NCT03208907 ↗ “Dihydroartemisinin-piperaquine for 3 days” NCT02453308 ↗ “Drug: Dihydroartemisinin piperaquine” NCT01624337 ↗ |
| Known as | Dihydroartemisinin, .beta.- | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | dihydroartemisinine | “MDA: 2 rounds of MDA with dihydroartemisinine-piperaquine + single low dose primaquine (PQ) administered instead of SMC round 1 and 5.” NCT07281443 ↗ |
| Known as | Dynamax | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | GNF-PF-5634 | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | Salaxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Known as | Santecxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗ |
| Modality | Small molecule | — CHEMBL307261 ↗ |
| Route | Oral | “dihydroartemisinin-piperaquine at an estimated total dosing of 6.75mg/kg of dihydroartemisinin and 55mg/kg of piperaquine for 3 days rounded to the nearest half tablet)” NCT01231113 ↗ |